ANTI-MAGE-1
|
|
- $425 - $667
- Product name: ANTI-MAGE-1
- CAS:
- MF:
- MW: 0
- EINECS:
- MDL Number:MFCD03096998
- Synonyms:Anti-ANKRD61 antibody produced in rabbit;Anti-MAGEA1 antibody produced in rabbit;ANTI-HUMAN MELANOMA-ASSOCIATED ANTIGEN 1 (MAGE-1);ANTI-MAGE-1;Anti-Melanoma antigen family A, 1 (directs expression of antigen MZ2-E);Anti-MGC9326;Anti-ankyrin repeat domain 61;Anti-KIAA1859
3 prices
Selected condition：
Brand
- Sigma-Aldrich
Package
- 100 μL
- 100μL
- ManufacturerSigma-Aldrich
- Product numberSAB2101417
- Product descriptionAnti-MAGEA1 antibody produced in rabbit affinity isolated antibody
- Packaging100μL
- Price$503
- Updated2023-01-07
- Buy
- ManufacturerSigma-Aldrich
- Product numberHPA029511
- Product descriptionAnti-ANKRD61 antibody produced in rabbit Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution
- Packaging100 μL
- Price$667
- Updated2026-04-30
- Buy
- ManufacturerSigma-Aldrich
- Product numberSAB2108038
- Product descriptionAnti-MAGEA1 antibody produced in rabbit IgG fraction of antiserum
- Packaging100μL
- Price$425
- Updated2023-01-07
- Buy
| Manufacturer | Product number | Product description | Packaging | Price | Updated | Buy |
|---|---|---|---|---|---|---|
| Sigma-Aldrich | SAB2101417 | Anti-MAGEA1 antibody produced in rabbit affinity isolated antibody | 100μL | $503 | 2023-01-07 | Buy |
| Sigma-Aldrich | HPA029511 | Anti-ANKRD61 antibody produced in rabbit Prestige Antibodies® Powered by Atlas Antibodies, affinity isolated antibody, buffered aqueous glycerol solution | 100 μL | $667 | 2026-04-30 | Buy |
| Sigma-Aldrich | SAB2108038 | Anti-MAGEA1 antibody produced in rabbit IgG fraction of antiserum | 100μL | $425 | 2023-01-07 | Buy |
Properties
storage temp. :-20°C
form :lyophilized powder
biological source :rabbit
form :lyophilized powder
biological source :rabbit
Safety Information
| Symbol(GHS): | ||||||||
|---|---|---|---|---|---|---|---|---|
| Signal word: | ||||||||
| Hazard statements: |
|
|||||||
| Precautionary statements: |
|